πŸ‡ΊπŸ‡Έ FDA
Patent

US 10828250

Topical formulation

granted A61KA61K31/07A61K31/192

Quick answer

US patent 10828250 (Topical formulation) held by LIMEWAY PHARMA DESIGN LIMITED expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
LIMEWAY PHARMA DESIGN LIMITED
Grant date
Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/07, A61K31/192, A61K31/203, A61K31/232